Biologic COPD RWD

Key criteria often include: Blood eosinophils ≥ 300 cells/µL, indicating Type 2–driven inflammation ≥ 2 moderate or severe exacerbations in the previous 12 months, despite standard treatment 

Pediatric patients

• Age: Adults
• Gender: Male and Female
• Diagnosis: ICD codes: From a medical informatics standpoint, this is how we’d expect these patients to be captured: * ICD-10 does not include a distinct code for the “biologic-eligible” COPD phenotype (i.e., the eosinophilic, frequent-exacerbator subgroup). Instead, you code the underlying COPD and its clinical manifestations. The most commonly used codes are:
  • J44.0 – Chronic obstructive pulmonary disease with (acute) lower respiratory infection i
  • J44.1 – Chronic obstructive pulmonary disease with (acute) exacerbation
  • J44.8 – Other specified chronic obstructive pulmonary disease
  • J44.9 – Chronic obstructive pulmonary disease, unspecified
  • If you need to capture coexisting emphysema or chronic bronchitis, you may also see:
    • J43.9 – Emphysema, unspecified
    • J42 – Chronic bronchitis
  • Unspecified Key point: “Biologic-eligible” is a clinical characterization (eosinophil count ≥300 cells/µL + frequent exacerbations) and isn’t reflected in the ICD-10 code itself. You’d use the appropriate J44.x code plus ancillary Z-codes or lab/documentation in the record to support phenotype-driven treatment decisions. 

• Latin America
• Middle East/Africa
• Asia-Pacific

“All ResearchNexo Data Collection must follow the ResearchNexo Data Collections Specifications“

Anonymized data set containing in CSV, excel or SQL formats.

• Demographic data (e.g., date of birth, gender, race, ethnicity)
• Conditions (e.g. ICD9 or ICD10 codes)
• Visits / Encounters (e.g., visit date, visit type)
• Procedures / Interventions (e.g., CPT or HCPCS codes or surgery names)
• Medications (e.g., drug name, dosage, formulation, NDC code)
• Reports (e.g., Radiology Reports, Clinical Notes)
• Lab Results
• Imaging Studies
• Genomics
• Claims